相关实验视频
Updated: Feb 19, 2026

Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
关于切换血小板P2Y12受体抑制疗法的国际专家共识
Dominick J Angiolillo1, Fabiana Rollini2, Robert F Storey3
1Division of Cardiology, University of Florida College of Medicine, Jacksonville (D.J.A., F.R., F.F.). dominick.angiolillo@jax.ufl.edu.
切换P2Y12抑制剂,包括口服药物如克洛皮多格勒,普拉苏格勒,提卡格勒和静脉格勒,是常见的,但缺乏明确的指导. 这份专家共识解决了安全问题,并提供了临床实践中治疗转换的建议.
科学领域:
- 心脏病学
- 药理学
- 血栓形成
背景情况:
- 使用阿司匹林和P2Y12抑制剂的双抗血小板治疗是急性冠状动脉综合征和皮肤冠状动脉干预的标准.
- 存在多种口服P2Y12抑制剂 (克洛皮多格雷尔,普拉苏格雷尔,蒂卡格雷尔) 和静脉注射的选择 (康格雷尔),导致频繁的治疗切换.
- 临床实践经常涉及由于各种因素而改变P2Y12抑制剂,但安全问题和指导方针缺乏明确性仍然存在.
研究的目的:
- 提供有关P2Y12抑制剂的药理学,方法和安全性的专家共识.
- 为临床医生提供关于何时以及如何切换P2Y12抑制剂治疗的指导.
- 解决当前实践指南中关于P2Y12抑制剂切换的有限建议.
主要方法:
- 由北美和欧洲领先的专家组成的专家共识文件.
- 对可用的P2Y12抑制剂的药理研究.
- 对切换策略和安全数据的现有文献进行分析.
主要成果:
- 该文件概述了转换P2Y12抑制剂的定义和方式.
- 它介绍了与切换相关的P2Y12抑制剂的药理学概述.
- 根据现有证据和专家意见提供安全有效的转换策略建议.
结论:
- 切换P2Y12抑制剂是一个复杂的临床场景,需要仔细考虑.
- 这份共识文件旨在通过提供实际建议来填补当前指导方针的空白.
- 坚持专家的共识可以提高患者的安全性,并优化抗血小板治疗的管理.
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Peripheral Artery Disease III: Interprofessional Care
Formation of the Platelet Plug
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Venous Thrombosis III: Interprofessional Care
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

